Plain-English translation of NCT03589729 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a medication called can protect your heart from damage caused by chemotherapy drugs used to treat blood cancers. Some chemotherapy medicines, especially one called , can weaken the heart over time. This study will give you the medication alongside your regular chemotherapy to see if it can prevent or reduce that heart damage.
Chemotherapy saves lives but can permanently damage the heart muscle, especially in people who receive certain powerful drugs. Doctors need to know if this medication can keep hearts healthy during cancer treatment, so patients can survive cancer without long-term heart problems.
You likely qualify if…
You likely don't qualify if…
You would receive the heart-protective medication as an infusion before or alongside your regular chemotherapy treatments. Your heart will be monitored closely throughout treatment using echocardiograms (heart ultrasounds) and blood tests to measure heart damage markers. The study will last at least 6 months, with regular clinic visits to check how you are tolerating both the medication and the chemotherapy.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States